Published in J Clin Psychiatry on April 01, 2004
IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun (2008) 1.30
Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin. J Neurovirol (2016) 0.75
Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus. Physiol Behav (2015) 0.75
Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry (2003) 2.13
Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 8.74
Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol (2005) 8.49
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology (2008) 4.35
When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry (2003) 3.68
Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry (2006) 3.33
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 3.24
Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry (2002) 3.05
Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry (2004) 2.83
Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun (2006) 2.78
Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun (2007) 2.75
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry (2013) 2.68
Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun (2005) 2.52
Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer (2003) 2.48
Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology (2011) 2.31
Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology (2008) 2.18
Impairments of reversal learning and response perseveration after repeated, intermittent cocaine administrations to monkeys. Neuropsychopharmacology (2002) 2.13
Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther (2011) 2.12
Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol (2006) 2.10
Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry (2003) 2.05
Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry (2008) 1.96
Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs (2005) 1.93
Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry (2003) 1.92
Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry (2003) 1.90
A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation (2004) 1.87
Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry (2005) 1.80
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend (2008) 1.73
The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: a multiple regression analysis. Depress Anxiety (2002) 1.72
Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry (2008) 1.70
Psychiatric comorbidity in persons with chronic fatigue syndrome identified from the Georgia population. Psychosom Med (2009) 1.69
Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology (2005) 1.65
Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol (2005) 1.63
Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology (2007) 1.63
Is depression an inflammatory disorder? Curr Psychiatry Rep (2011) 1.60
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry (2005) 1.58
Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.56
Major depression drives severity of American Urological Association Symptom Index. Urology (2010) 1.54
IPSS quality of life question: a possible indicator of depression among patients with lower urinary tract symptoms. Can J Urol (2012) 1.54
Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry (2007) 1.51
Characterization of an interleukin-6- and adrenocorticotropin-dependent, immune-to-adrenal pathway during viral infection. Endocrinology (2004) 1.51
Adherence to the mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study. Circulation (2007) 1.51
Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry (2012) 1.48
Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety (2013) 1.48
Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun (2004) 1.43
Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol (2010) 1.38
Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci (Landmark Ed) (2009) 1.38
Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs (2006) 1.37
Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol (2012) 1.35
Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacol Biochem Behav (2005) 1.31
IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun (2008) 1.30
Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci (2009) 1.30
Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord (2009) 1.28
Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry (2008) 1.27
MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) (2006) 1.26
Pituitary-adrenal responses to standard and low-dose dexamethasone suppression tests in adult survivors of child abuse. Biol Psychiatry (2004) 1.26
Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl) (2005) 1.26
Effects of mindful-attention and compassion meditation training on amygdala response to emotional stimuli in an ordinary, non-meditative state. Front Hum Neurosci (2012) 1.24
Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol Psychiatry (2010) 1.14
Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. Am J Addict (2008) 1.13
Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology (2007) 1.13
Compassion meditation enhances empathic accuracy and related neural activity. Soc Cogn Affect Neurosci (2012) 1.13
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry (2010) 1.13
Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun (2012) 1.11
Breast cancer and depression. Oncology (Williston Park) (2004) 1.08
Methamphetamine craving induced in an online virtual reality environment. Pharmacol Biochem Behav (2010) 1.07
Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with chronic fatigue syndrome. Psychosom Med (2008) 1.06
Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther (2012) 1.04
Theories of addiction: methamphetamine users' explanations for continuing drug use and relapse. Am J Addict (2009) 1.04
Inhibition of Jun N-terminal kinase (JNK) enhances glucocorticoid receptor-mediated function in mouse hippocampal HT22 cells. Neuropsychopharmacology (2005) 1.01
Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study. Psychosom Med (2008) 1.01
Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology (2005) 1.00
Association between posttraumatic stress disorder and inflammation: a twin study. Brain Behav Immun (2013) 0.99
Noradrenergic α₁ receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. PLoS One (2012) 0.99
Genetic and environmental influences on systemic markers of inflammation in middle-aged male twins. Atherosclerosis (2008) 0.99
Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav Immun (2013) 0.98
Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol (2011) 0.98
The Inventory of Callous and Unemotional Traits: a construct-validational analysis in an at-risk sample. Assessment (2013) 0.98
Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer (2013) 0.97
Innate immune, neuroendocrine and behavioral responses to psychosocial stress do not predict subsequent compassion meditation practice time. Psychoneuroendocrinology (2009) 0.96
Nocturia associated with depressive symptoms. Urology (2011) 0.96
Treatment of cytokine-induced depression. Brain Behav Immun (2002) 0.94
Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol (2009) 0.93
Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology (2013) 0.93
Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ Cardiovasc Genet (2009) 0.93
A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. Pharmacol Biochem Behav (2006) 0.92
Interferon-alpha inhibits glucocorticoid receptor-mediated gene transcription via STAT5 activation in mouse HT22 cells. Brain Behav Immun (2009) 0.92
Modafinil administration improves working memory in methamphetamine-dependent individuals who demonstrate baseline impairment. Am J Addict (2010) 0.92
Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain Behav Immun (2011) 0.92
Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol (2008) 0.92
The relationship between impulsivity and craving in cocaine- and methamphetamine-dependent volunteers. Pharmacol Biochem Behav (2011) 0.92
The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial. PLoS One (2012) 0.92
Painful diabetic neuropathy is more than pain alone: examining the role of anxiety and depression as mediators and complicators. Curr Diab Rep (2011) 0.91
Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse. Schizophr Res (2004) 0.91